Skip to main content

Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia

Medically reviewed by Carmen Pope, BPharm. Last updated on June 24, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, June 24, 2024 -- For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields comparable relapse incidence (RI) and significantly lower incidence of GVHD than conventional prophylaxis, according to a study published online June 10 in the American Journal of Hematology.

Arnon Nagler, M.D., from the Sheba Medical Center in Tel Hashomer, Israel, and colleagues compared RI post-unrelated allogeneic stem cell transplantation with PTCy versus conventional GVHD prophylaxis among 7,049 AML patients in remission (707 with PTCy; 6,342 with No PTCy).

The researchers found that RI did not differ significantly in the PTCy versus the no PTCy group. The PTCy group had significantly lower acute GVHD grades II to IV and III to IV versus the No PTCy group (hazard ratios, 0.74 and 0.56, respectively), and total and extensive chronic GVHD (hazard ratios, 0.5 and 0.31, respectively). Compared with the No PTCy group, the PTCy group had significantly lower nonrelapse mortality (hazard ratio, 0.67). Significantly higher GVHD-free, relapse-free survival was seen in the PTCy versus the No PTCy group (hazard ratio, 0.69). The groups did not differ in terms of leukemia-free survival or overall survival.

"Clinically, these results are of importance, and although not direct proof, they may indicate that PTCy does not jeopardize the graft-versus-leukemia effect in the unrelated donor setting," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2024

Read this next

Trametinib Safe, Effective for Juvenile Myelomonocytic Leukemia

TUESDAY, June 18, 2024 -- For children with relapsed or refractory juvenile myelomonocytic leukemia (JMML), trametinib is safe and effective, according to a study published online...

Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy

FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...

Positive Psychology Intervention Aids Allogeneic Stem Cell Transplant Survivors

THURSDAY, June 13, 2024 -- A telephone-delivered positive psychology intervention (Positive Affect for the Transplantation of Hematopoietic stem cells intervention [PATH]) is...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.